The European Patent Office’s Board of Appeal has found in favour of bioMérieux in the opposition to its European patent for the Boom technology.
A world leader in the field of in vitro diagnostics, with over 40 years experience in infectious diseases, bioMérieux SA recently confirmed its commitment to the field of emergency diagnostics through its presence at the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels on March 21–25, 2005.
NucliSens® miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.
bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.
U.S. FDA Premarket Notification 510(k) Clearance of Polycarbonate BacT/ALERT® Culture Bottles for Microbial QC Testing of Leukocyte-Reduced Single Units of Whole Blood Platelet Concentrates (WBPC)
bioMérieux announces U.S. FDA-CBER (1) Premarket Notification 510(k) clearance of the recently launched, innovative polycarbonate BacT/ALERT BPA and BacT/ALERT BPN culture bottles for microbial quality control testing of leukocyte-reduced single units of whole blood platelet concentrates (WBPC).
bioMérieux, a major player in the field of microbiological controls for the pharmaceutical and agri-food industries, introduces VITEK®2 Compact, the newest addition to its range of automated identification systems.
bioMérieux has received CE Mark certifications for all of its in vitro diagnostic (IVD) products currently marketed in the European Union (EU). In compliance with the requirements of the 98/79/EC directive for CE Marking, which became applicable on December 7th, 2003, these certifications enable bioMérieux to continue to sell its products within the European Union after this date.